Q32 Bio Inc. (QTTB) stock
QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.53−0.10 (-1.16%)
Close on Nov 18, 2026Market cap $253.93MP/E –Yield –
Q32 Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Q32 Bio's operating income for the twelve months ending Jun 30, 2026 was $21.46M. For fiscal 2025 it was $16.90M. The highest annual figure on record is $16.90M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.90M | – |
| FY2024 | Dec 31, 2024 | -$66.10M | – |
| FY2023 | Dec 31, 2023 | -$48.26M | – |
| FY2022 | Dec 31, 2022 | -$133.28M | – |
| FY2021 | Dec 31, 2021 | -$95.95M | – |
| FY2020 | Dec 31, 2020 | -$130.26M | – |
| FY2019 | Dec 31, 2019 | -$109.94M | – |
| FY2018 | Dec 31, 2018 | -$59.93M | – |
| FY2017 | Dec 31, 2017 | -$29.66M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.12M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.72M | – |
| Q4 FY2025 | Dec 31, 2025 | $45.88M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.58M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.17M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.23M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.53M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.81M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.92M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.84M | – |
| Q4 FY2023 | Dec 31, 2023 | -$25.81M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.80M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.28M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.37M | – |
| Q4 FY2022 | Dec 31, 2022 | -$34.49M | – |
| Q3 FY2022 | Sep 30, 2022 | -$32.86M | – |
| Q2 FY2022 | Jun 30, 2022 | -$28.31M | – |
| Q1 FY2022 | Mar 31, 2022 | -$37.62M | – |
| Q4 FY2021 | Dec 31, 2021 | -$33.63M | – |
| Q3 FY2021 | Sep 30, 2021 | -$30.66M | – |
| Q2 FY2021 | Jun 30, 2021 | -$30.55M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.11M | – |
| Q4 FY2020 | Dec 31, 2020 | -$29.80M | – |
| Q3 FY2020 | Sep 30, 2020 | -$28.27M | – |
| Q2 FY2020 | Jun 30, 2020 | -$35.70M | – |
| Q1 FY2020 | Mar 31, 2020 | -$36.49M | – |
| Q4 FY2019 | Dec 31, 2019 | -$25.56M | – |
| Q3 FY2019 | Sep 30, 2019 | -$31.29M | – |
| Q2 FY2019 | Jun 30, 2019 | -$27.97M | – |
| Q1 FY2019 | Mar 31, 2019 | -$25.12M | – |
| Q4 FY2018 | Dec 31, 2018 | -$20.17M | – |
| Q3 FY2018 | Sep 30, 2018 | -$15.64M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.42M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.70M | – |
| Q4 FY2017 | Dec 31, 2017 | -$12.26M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.66M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.04M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.69M | – |
See a number that looks wrong?